Know where to look next.
Treelip turns complex public clinical, patent, regulatory, and biomarker records into explainable signals for research, diligence, and strategic planning.
Clinical Program Risk Radar
Focus diligence on oncology Phase 2 assets with public signals for delays, terminations, recruitment burden, and missing results.
Generic Entry Radar
Screen U.S. small-molecule products for potential loss-of-exclusivity windows, with public expiry and patent-complexity signals in one view.
ADC Target Strategy Radar
Compare oncology ADC targets through clinical crowding, sponsor activity, patent-density signals, and strategic labels.
Translational Deal Radar
Identify translational programs that merit deeper diligence using public clinical momentum, IP-linkage, and BD-relevance signals.
Protocol Benchmark Radar
Compare public trial designs by endpoint precedent, eligibility burden, biomarker strategy, and operational considerations.
Biomarker Patient-Selection Radar
See how oncology biomarkers are used for patient selection alongside FDA companion-diagnostic context and diagnostic patent-density signals.
Built for a specific question
Public biomedical databases contain valuable evidence, but raw search results are difficult to compare. Each Treelip module organizes the relevant records around a practical research or strategy question.
Evidence stays visible
Signals are clearly labelled and tied to public source records and methodology. Treelip is designed to support expert review, not to hide judgment behind a black-box score.
Start broad, investigate deeply
Use the dashboards to identify where attention may be warranted, then bring the underlying records, your team's expertise, and deeper diligence to the decision.
A practical starting point for pharma strategy
Treelip is an independent platform for pharma, biotech, diagnostics, and investment teams. Its focused intelligence modules organize publicly available data from sources including FDA resources, ClinicalTrials.gov, and related public records into useful first-pass views for BD, strategy, and market intelligence work.
The outputs are designed for first-pass prioritization and expert review support, not automated decisions. Treelip does not replace clinical, legal, regulatory, or investment judgment; it helps experts decide what to investigate next.
Ways to work with Treelip: Public dashboards · Gated CSV exports · Custom asset or target reports · Watchlist monitoring.
Bring a sharper starting point to your next review
Register your interest to request access, receive relevant product updates, or discuss a focused asset, target, or therapeutic-area question.